Syneos Health — Jefferies Virtual Healthcare Conference 2020
19 slides from Syneos Health's conference presentation, Jun 3, 2020
Slide 1: Jefferies Virtual Healthcare Conference
Exhibit 99.1 Jefferies Virtual Healthcare Conference Alistair Macdonald Chief Executive Officer June 3, 2020
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this EBITDA, adjusted EBITDA, and adjusted EBITDA margin. We also include in this presentation non-GAAP presentat
Slide 3: Market Leader Purpose-Built for Biopharmaceutical Acceleration
Market Leader Purpose-Built for Biopharmaceutical Acceleration Clinical Solutions TOP % of 3 74% CRO TTM # 1 Adjusted CCO Only Revenue 26% end-to-end biopharma Commercial Solutions product development organization in the world >$75B >90% combined market of FDA approved Novel Syneos One™ opportunity
Slide 4: Purpose-Built to Address Unique Clinical Development Needs
Purpose-Built to Address Unique Clinical Development Needs Flexibility to Improve the Likelihood of Regulatory and Commercial Success Differentiators Uniquely Support Market Segmentation Early Phase Scientific Affairs & Reporting Proof of Concept Catalyst Translational Sciences Site Network Geograph
Slide 5: Expanding Clinical Share Positions for Continued Growth
Expanding Clinical Share Positions for Continued Growth Share Strength and Opportunity 3 Strategic wins with Top 30 Pharma since Q1 18 <5% ~15% Strong position with 21 - 50 Market ~10% Market where flexibility matters Share Market Share Share Top 20 Pharma 21 - 50 Pharma SMID CRO Market Outsourced C
Slide 6: Building Momentum with Large Pharma
Building Momentum with Large Pharma Preferred Provider Wins with Top 30 Pharma Demonstrate the Strength of our Unique Capabilities … you won this work because you understand our goals and vision, the combination of your clinical and “commercial capabilities, and the fact that you consider patients a
Slide 7: Commercial Industry Leader Positioned for the Modern Market
Commercial Industry Leader Positioned for the Modern Market Unparalleled Breadth of Capabilities Uniquely Positioned for a Dynamic Market Deployment Solutions Field-Based Promotional Solutions and Clinical Teams Strategy Design Recruiting 61% Sales Operations Market >15% Growth 2 Engagement Center L
Slide 8: Syneos One: Unique End-to-End Integrated Product Development Offering
Syneos One™: Unique End-to-End Integrated Product Development Offering Driving Awards and Pipeline Differentiated product offering in the market $1.4B $475M+ Improves speed to market through integrated early planning, design and execution estimated potential of TTM Clinical and Focused on maximizing
Slide 9: COVID-19 Response and Mitigating Actions
COVID-19 Response and Mitigating Actions % of TTM Mitigating Revenue Actions Full-Service 60% • On track to convert 70 – 80% of Q2 visits to Clinical Remote Monitoring • Working non-Site Activities in SSU • Remote Monitoring of existing patients • Recruitment in less affected regions COVID-19 Public
Slide 10: Focus on Margin Enhancement Drives Shareholder Value
Focus on Margin Enhancement Drives Shareholder Value Targeting 13 – 14% FY 2020 Adjusted EBITDA margin1 and 30 – 50 bps of margin expansion in 2021 COVID-19 Cost Management & Liquidity Preservation Actions • Accelerated ForwardBound margin enhancement initiative • Implemented temporary cost actions
Slide 11: Balanced Approach to Capital Deployment
Balanced Approach to Capital Deployment Successfully Managing our Capital Structure and Related Costs Debt Reduction Tuck-in Acquisitions Share and Management and Strategic Partnerships Repurchases Redeemed 7.5% Senior Notes in Q4 2019 Continue to review tuck-in acquisition and Board approved extens
Slide 12: Q2 2020 Outlook
Q2 2020 Outlook $M (except margin, growth rate, and per share data) Guidance Range Growth Rate Revenue1,2 $ 1,000 - $ 1,020 (14.4) % – (12.7) % Adjusted EBITDA $ 107 - $ 117 (30.4) % – (23.9) % Adjusted EBITDA Margin3 10.7% - 11.5% Adjusted Diluted EPS $ 0.48 - $0.52 (35.1) % – (29.7) % Note: Financ
Slide 13: Investment Summary: Driving Shareholder Value
Investment Summary: Driving Shareholder Value Comprehensive Fit-for-Purpose Unique Syneos One™ Product Development Insights across Clinical product offering solutions and Commercial $ $ $ Increasing share and Value creation Balanced momentum via capital deployment with Margin Enhancement Large Pharm
Slide 14: Shortening the Distance From Lab to Life
Shortening the Distance From Lab to Life®.
Slide 15: Appendix
Appendix 15
Slide 16: Q2 2020 Guidance Reconciliation: Adjusted Net Income and Adjusted Diluted EPS
Q2 2020 Guidance Reconciliation Adjusted Net Income and Adjusted Diluted EPS Adjusted Net Income Adjusted Diluted Earnings Per Share $M (except per share data) Low High Low High GAAP Net Loss and Diluted Loss per Share $ (6.3) $ (3.5) $ (0.06) $ (0.03) Adjustments: Amortization1 39.0 39.0 0.37 0.37
Slide 17: Q2 2020 Guidance Reconciliation: Adjusted EBITDA
Q2 2020 Guidance Reconciliation Adjusted EBITDA $M Low High GAAP Net Loss $ (6.3) $ (3.5) Adjustments: Interest Expense, Net1 23.0 25.0 Income Tax Expense1 (2.7) (1.5) Depreciation1 18.0 20.0 Amortization1 39.0 39.0 EBITDA 71.0 79.0 Restructuring and Other Costs1 15.0 15.0 Transaction Expenses1 4.0
Slide 18: Reconciliation of GAAP Revenue by Segment to Adjusted Revenue by Segment
Reconciliation of GAAP Revenue by Segment to Adjusted Revenue by Segment $M Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Clinical Solutions revenue, as reported $ 783.9 $ 819.2 $ 821.2 $ 805.0 $ 849.9 $ 867.4 $ 899.3 $ 874.8 Clinical Solutions deferred revenue adjustment (a) 3.4 2.9 2.9 1.6 1.6 1
Slide 19: Shortening the Distance From Lab to Life
Shortening the Distance From Lab to Life®.
Syneos Health — Jefferies Virtual Healthcare Conference 2020 on 6ix